Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopeniaRalph V. Boccia, James B. Bussel, Quentin A. Hill et al.|British Journal of Haematology|2020Cited by 71
Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) PatientsRalph V. Boccia, James B. Bussel, Michael Boxer et al.|Blood|2019Cited by 3